Case West­ern/Sang­amo get $11M grant to wipe out HIV; Sage's de­pres­sion drug, GSK's vac­cine get break­through ther­a­py des­ig­na­tion

→ Pri­vate uni­ver­si­ty Case West­ern Re­serve and Sang­amo Ther­a­peu­tics $SG­MO have scored an $11 mil­lion grant from the Na­tion­al In­sti­tutes of Health to study gene-edit­ed T cells that would com­plete­ly wipe out HIV. The grant will fund a clin­i­cal tri­al test­ing the hy­poth­e­sis that treat­ing pa­tients with their own gene-edit­ed T cells may lead to a sus­tained boost in T cell counts and the erad­i­ca­tion of la­tent HIV reser­voirs. Cur­rent treat­ments for HIV don’t cure in­fect­ed peo­ple due to the per­sis­tence of a la­tent HIV pop­u­la­tion, the com­pa­nies said in a joint state­ment. Sang­amo Ther­a­peu­tics will be con­tribut­ing ma­te­ri­als, equip­ment, and man­u­fac­tur­ing ex­per­tise for the study, which is ex­pect­ed to be­gin in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER